Thrombocytopenia Market 2027
DelveInsight's 'Thrombocytopenia - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Thrombocytopenia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Thrombocytopenia from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2016-2027
Thrombocytopenia - Disease Understanding and Treatment Algorithm
The DelveInsight Thrombocytopenia market report gives the thorough understanding of the Thrombocytopenia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Thrombocytopenia in the US, Europe, and Japan.
Thrombocytopenia Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, prevalent cases by type, prevalent cases by age, prevalent and diagnosed cases of Idiopathic Thrombocytopenic Purpura (ITP), Chemotherapy-Induced Thrombocytopenia (CIT), Heparin-Induced Thrombocytopenia (HIT) and Thrombocytopenia associated with Chronic Liver Disease (CLD)) scenario of Thrombocytopenia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the total number of prevalent population of Thrombocytopenia was found to be 817,855, in the year 2016.
Thrombocytopenia Drug Chapters
This segment of the Thrombocytopenia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are several approved therapies, capturing one or the other Thrombocytopenia related causes. N-plate (Amgen) and Promacta (GSK) are the approved drugs for the treatment of patients with chronic immune thrombocytopenic purpura. Octagam (Octapharm USA) is indicated for the treatment of idiopathic thrombocytopenic purpura. Detailed chapter for upcoming therapies like SHP-655 (Shire), Avatrombopag (Dova Pharmaceuticals), BT-595 (Biotest) and Caplacizumab (Ablynx) have been covered in the report.
Thrombocytopenia Market Outlook
The Thrombocytopenia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Thrombocytopenia in 7MM was found to be USD 1,248 million in 2016.
Thrombocytopenia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Thrombocytopenia Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Thrombocytopenia Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Thrombocytopenia Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Thrombocytopenia market
• Organize sales and marketing efforts by identifying the best opportunities for Thrombocytopenia market
• To understand the future market competition in the Thrombocytopenia market
1. Key Insights
2. Thrombocytopenia Market Overview at a Glance
2.1. Market Share (%) Distribution of Thrombocytopenia in 2017
2.2. Market Share (%) Distribution of Thrombocytopenia in 2027
3. Disease Background and Overview: Thrombocytopenia
3.1. Introduction
3.2. Causes of Thrombocytopenia
3.3. Pathogenesis
3.4. Pathophysiology
3.5. Etiology
3.6. Symptoms
3.7. Diagnosis and Treatment
3.8. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
3.9. Management of thrombocytopenia
3.10. First Line Therapies
3.11. Second and Third Line Therapies
3.12. Diagnostic and treatment guidelines form thrombotic thrombocytopenic purpura (TTP) 2017 in Japan
3.13. Treatment of Heparin-induced Thrombocytopenia (HIT)
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Prevalent Population of Thrombocytopenia
4.4. Country Wise-Epidemiology of Thrombocytopenia
4.4.1. United States
4.4.1.1. Prevalent cases of Thrombocytopenia in the United States
4.4.1.2. Prevalent cases of Thrombotic Thrombocytopenic Purpura (TTP) by Type in the United States
4.4.1.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in the United States
4.4.1.4. Prevalent cases of Idiopathic Thrombocytopenic Purpura (ITP) in the United States
4.4.1.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in the United States
4.4.1.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in the United States
4.4.1.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in the United States
4.4.1.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United States
4.4.1.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in the United States
4.4.1.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in the United States
4.4.1.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in the United States
4.4.1.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in the United States
4.4.2. Germany
4.4.2.1. Prevalent cases of Thrombocytopenia in Germany
4.4.2.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in Germany
4.4.2.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in Germany
4.4.2.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in Germany
4.4.2.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Germany
4.4.2.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in Germany
4.4.2.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Germany
4.4.2.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Germany
4.4.2.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in Germany
4.4.2.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Germany
4.4.2.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in Germany
4.4.2.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Germany
4.4.3. France
4.4.3.1. Prevalent cases of Thrombocytopenia in France
4.4.3.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in France
4.4.3.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in France
4.4.3.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in France
4.4.3.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in France
4.4.3.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in France
4.4.3.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in France
4.4.3.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in France
4.4.3.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in France
4.4.3.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in France
4.4.3.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in France
4.4.3.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in France
4.4.4. Italy
4.4.4.1. Prevalent cases of Thrombocytopenia in Italy
4.4.4.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in Italy
4.4.4.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in Italy
4.4.4.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in Italy
4.4.4.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Italy
4.4.4.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in Italy
4.4.4.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Italy
4.4.4.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Italy
4.4.4.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in Italy
4.4.4.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Italy
4.4.4.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in Italy
4.4.4.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Italy
4.4.5. Spain
4.4.5.1. Prevalent cases of Thrombocytopenia in Spain
4.4.5.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in Spain
4.4.5.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in Spain
4.4.5.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in Spain
4.4.5.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Spain
4.4.5.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in Spain
4.4.5.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Spain
4.4.5.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Spain
4.4.5.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in Spain
4.4.5.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Spain
4.4.5.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in Spain
4.4.5.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Spain
4.4.6. United Kingdom
4.4.6.1. Prevalent cases of Thrombocytopenia in the United Kingdom
4.4.6.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in the United Kingdom
4.4.6.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in the United Kingdom
4.4.6.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in the United Kingdom
4.4.6.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in the United Kingdom
4.4.6.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in the United Kingdom
4.4.6.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in the United Kingdom
4.4.6.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United Kingdom
4.4.6.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in the United Kingdom
4.4.6.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in the United Kingdom
4.4.6.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in the United Kingdom
4.4.6.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in the United Kingdom
4.4.7. Japan
4.4.7.1. Prevalent cases of Thrombocytopenia in Japan
4.4.7.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in Japan
4.4.7.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in Japan
4.4.7.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in Japan
4.4.7.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Japan
4.4.7.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in Japan
4.4.7.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Japan
4.4.7.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Japan
4.4.7.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in Japan
4.4.7.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Japan
4.4.7.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in Japan
4.4.7.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Japan
5. Unmet needs
6. Marketed Products
7. Octagam: Octapharma USA
7.1. Product Description
7.2. Regulatory Milestones
7.3. Advantages & Disadvantages
7.4. Safety and Efficacy of Octagam
7.5. Side effects of Octagam
7.6. Product Profile
8. Nplate(AMG-531): Amgen
8.1. Product Description
8.2. Regulatory Milestones
8.3. Advantages & Disadvantages
8.4. Safety and Efficacy of Nplate
8.5. Side effects of Nplate
8.6. Product Profile
9. MULPLETA (Lusutrombopag): Shionogi
9.1. Product Description
9.2. Regulatory Milestones
9.3. Safety and Efficacy of Lusutrombopag/MULPLETA
9.4. Side effects of MULPLETA
9.5. Product Profile
10. Privigen: CSL Behring
10.1. Product Description
10.2. Regulatory Milestones
10.3. Advantages & Disadvantages
10.4. Safety and Efficacy of Privigen
10.5. Side effects of Privigen
10.6. Product Profile
11. Rhophylac: CSL Behring
11.1. Product Description
11.2. Regulatory Milestones
11.3. Advantages & Disadvantages
11.4. Safety and Efficacy of Rhophylac
11.5. Side effects of Rhophylac
11.6. Product Profile
12. Emerging Therapies
13. Filed & Phase III Drugs
13.1. Avatrombopag: Dova Pharmaceuticals
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and efficacy
13.1.8. Advantages and Disadvantages
13.2. Fostamatinib: Rigel Pharmaceuticals
13.2.1. Drug Description
13.2.2. Product Profile
13.2.3. Regulatory Milestones
13.2.4. Clinical Development
13.2.5. Clinical Trials Information
13.2.6. Safety and efficacy
13.2.7. Advantages and Disadvantages
13.3. Caplacizumab: Ablynx
13.3.1.1. Drug Description
13.3.1.2. Product Profile
13.3.1.3. Regulatory Milestones
13.3.1.4. Other Development Activities
13.3.1.5. Clinical Development
13.3.1.6. Clinical Trials Information
13.3.1.7. Safety and efficacy
13.3.1.8. Advantages and Disadvantages
13.4. BT-595: Biotest
13.4.1. Drug Description
13.4.2. Product Profile
13.4.3. Other Development Activities
13.4.4. Clinical Development
13.4.5. Clinical Trials Information
13.4.6. Advantages and Disadvantages
13.5. SHP655: Shire
13.5.1. Drug Description
13.5.2. Product Profile
13.5.3. Regulatory Milestones
13.5.4. Other Development Activities
13.5.5. Clinical Development
13.5.6. Clinical Trials Information
13.5.7. Safety and Efficacy
13.5.8. Advantages and Disadvantages
14. Phase II Drugs
14.1. PRN-1008: Principia Biopharma
14.1.1. Drug Description
14.1.2. Product Profile
14.1.3. Other Development Activities
14.1.4. Clinical Development
14.1.5. Clinical Trials Information
14.2. PRTX-100: Protalex
14.2.1. Drug Description
14.2.2. Product Profile
14.2.3. Regulatory Milestones
14.2.4. Clinical Development
14.2.5. Clinical Trials Information
14.2.6. Safety and Efficacy
14.2.7. Advantages and Disadvantages
14.3. Rozanolixizumab: UCB Biopharma
14.3.1. Drug Description
14.3.2. Product Profile
14.3.3. Other Development Activities
14.3.4. Clinical Development
14.3.5. Clinical Trials Information
14.3.6. Safety and efficacy
14.4. Efgartigimod: Argenx
14.4.1. Drug Description
14.4.2. Product Profile
14.4.3. Other Development Activities
14.4.4. Clinical Development
14.4.5. Clinical Trials Information
14.4.6. Safety and efficacy
14.5. Veltuzumab: Immunomedics
14.5.1. Drug Description
14.5.2. Product Profile
14.5.3. Regulatory Milestones
14.5.4. Other Development Activities
14.5.5. Clinical Development
14.5.6. Clinical Trials Information
14.5.7. Safety and efficacy
15. Thrombocytopenia: Market Analysis
15.1. Key Findings
16. Thrombocytopenia: Total Market Size in 7MM
16.1. Total Market Size of Thrombocytopenia in 7MM
16.2. Type Specific Market Size of Thrombocytopenia in 7MM
17. Market Size of Thrombocytopenia by Country
17.1. United States Market Analysis
17.1.1. Market Size of Thrombocytopenia in the US
17.1.2. Type Specific Market Size of Thrombocytopenia in the US
17.1.3. Market Size of TTP in the US
17.1.4. Therapy Based Market Size of TTP in the US
17.1.5. Therapy Based Market Size of ITP in the US
17.2. Thrombocytopenia: EU5 Market Outlook
17.3. Germany
17.3.1. Market Size of Thrombocytopenia in Germany
17.3.2. Type Specific Market Size of Thrombocytopenia in Germany
17.3.3. Market Size of TTP in Germany
17.3.4. Therapy Based Market Size of TTP in Germany
17.3.5. Therapy Based Market Size of ITP in Germany
17.4. France
17.4.1. Market Size of Thrombocytopenia in France
17.4.2. Type Specific Market Size of Thrombocytopenia in France
17.4.3. Market Size of TTP in France
17.4.4. Therapy Based Market Size of TTP in France
17.4.5. Therapy Based Market Size of ITP in France
17.5. Italy
17.5.1. Market Size of Thrombocytopenia in Italy
17.5.2. Type Specific Market Size of Thrombocytopenia in Italy
17.5.3. Market Size of TTP in Italy
17.5.4. Therapy Based Market Size of TTP in Italy
17.5.5. Therapy Based Market Size of ITP in Italy
17.6. Spain
17.6.1. Market Size of Thrombocytopenia in Spain
17.6.2. Type Specific Market Size of Thrombocytopenia in Spain
17.6.3. Market Size of TTP in Spain
17.6.4. Therapy Based Market Size of TTP in Spain
17.6.5. Therapy Based Market Size of ITP in Spain
17.7. United Kingdom
17.7.1. Market Size of Thrombocytopenia in the UK
17.7.2. Type Specific Market Size of Thrombocytopenia in the UK
17.7.3. Market Size of TTP in the UK
17.7.4. Therapy Based Market Size of TTP in the UK
17.7.5. Therapy Based Market Size of ITP in the UK
17.8. Japan: Market Analysis
17.8.1. Market Size of Thrombocytopenia in Japan
17.8.2. Type Specific Market Size of Thrombocytopenia in Japan
17.8.3. Therapy Based Market Size of ITP in Japan
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Table 1: First-Line Treatment Options for Immune Thrombocytopenia
Table 2: Second- and Third-Line Treatment Options for Immune Thrombocytopenia
Table 3: Prevalent Population of Thrombocytopenia in 7MM (2016-2027)
Table 4: Prevalent Cases of Thrombocytopenia in the United States (2016-2027)
Table 5: Prevalent Cases of TTP by Type in the United States (2016-2027)
Table 6: Prevalent Cases of TTP by Age in the United States (2016-2027)
Table 7: Prevalent Cases of ITP in the United States (2016-2027)
Table 8: Prevalent cases of CIT in the United States (2016-2027)
Table 9: Prevalent cases of HIT in the United States (2016-2027)
Table 10: Prevalent cases of Thrombocytopenia associated with CLD in the United States (2016-2027)
Table 11: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United States (2016-2027)
Table 12: Diagnosed Cases of ITP in the United States (2016-2027)
Table 13: Diagnosed cases of CIT in the United States (2016-2027)
Table 14: Diagnosed cases of HIT in the United States (2016-2027)
Table 15: Diagnosed cases of Thrombocytopenia associated with CLD in the United States (2016-2027)
Table 16: Prevalent Cases of Thrombocytopenia in Germany (2016-2027)
Table 17: Prevalent Cases of TTP by Type in Germany (2016-2027)
Table 18: Prevalent Cases of TTP by Age in Germany (2016-2027)
Table 19: Prevalent Cases of ITP in Germany (2016-2027)
Table 20: Prevalent cases of CIT in Germany (2016-2027)
Table 21: Prevalent cases of HIT in Germany (2016-2027)
Table 22: Prevalent cases of Thrombocytopenia associated with CLD in Germany (2016-2027)
Table 23: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Germany (2016-2027)
Table 24: Diagnosed Cases of ITP in Germany (2016-2027)
Table 25: Diagnosed cases of CIT in Germany (2016-2027)
Table 26: Diagnosed cases of HIT in Germany (2016-2027)
Table 27: Diagnosed cases of Thrombocytopenia associated with CLD in Germany (2016-2027)
Table 28: Prevalent Cases of Thrombocytopenia in France (2016-2027)
Table 29: Prevalent Cases of TTP by Type in France (2016-2027)
Table 30: Prevalent Cases of TTP by Age in France (2016-2027)
Table 31: Prevalent Cases of ITP in France (2016-2027)
Table 32: Prevalent cases of CIT in France (2016-2027)
Table 33: Prevalent cases of HIT in France (2016-2027)
Table 34: Prevalent cases of Thrombocytopenia associated with CLD in France (2016-2027)
Table 35: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in France (2016-2027)
Table 36: Diagnosed Cases of ITP in France (2016-2027)
Table 37: Diagnosed cases of CIT in France (2016-2027)
Table 38: Diagnosed cases of HIT in France (2016-2027)
Table 39: Diagnosed cases of Thrombocytopenia associated with CLD in France (2016-2027)
Table 40: Prevalent Cases of Thrombocytopenia in Italy (2016-2027)
Table 41: Prevalent Cases of TTP by Type in Italy (2016-2027)
Table 42: Prevalent Cases of TTP by Age in Italy (2016-2027)
Table 43: Prevalent Cases of ITP in Italy (2016-2027)
Table 44: Prevalent cases of CIT in Italy (2016-2027)
Table 45: Prevalent cases of HIT in Italy (2016-2027)
Table 46: Prevalent cases of Thrombocytopenia associated with CLD in Italy (2016-2027)
Table 47: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Italy (2016-2027)
Table 48: Diagnosed Cases of ITP in Italy (2016-2027)
Table 49: Diagnosed cases of CIT in Italy (2016-2027)
Table 50: Diagnosed cases of HIT in Italy (2016-2027)
Table 51: Diagnosed cases of Thrombocytopenia associated with CLD in Italy (2016-2027)
Table 52: Prevalent Cases of Thrombocytopenia in Spain (2016-2027)
Table 53: Prevalent Cases of TTP by Type in Spain (2016-2027)
Table 54: Prevalent Cases of TTP by Age in Spain (2016-2027)
Table 55: Prevalent Cases of ITP in Spain (2016-2027)
Table 56: Prevalent cases of CIT in Spain (2016-2027)
Table 57: Prevalent cases of HIT in Spain (2016-2027)
Table 58: Prevalent cases of Thrombocytopenia associated with CLD in Spain (2016-2027)
Table 59: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Spain (2016-2027)
Table 60: Diagnosed Cases of ITP in Spain (2016-2027)
Table 61: Diagnosed cases of CIT in Spain (2016-2027)
Table 62: Diagnosed cases of HIT in Spain (2016-2027)
Table 63: Diagnosed cases of Thrombocytopenia associated with CLD in Spain (2016-2027)
Table 64: Prevalent Cases of Thrombocytopenia in the United Kingdom (2016-2027)
Table 65: Prevalent Cases of TTP by Type in the United Kingdom (2016-2027)
Table 66: Prevalent Cases of TTP by Age in the United Kingdom (2016-2027)
Table 67: Prevalent Cases of ITP in the United Kingdom (2016-2027)
Table 68: Prevalent cases of CIT in the United Kingdom (2016-2027)
Table 69: Prevalent cases of HIT in the United Kingdom (2016-2027)
Table 70: Prevalent cases of Thrombocytopenia associated with CLD in the United Kingdom (2016-2027)
Table 71: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United Kingdom (2016-2027)
Table 72: Diagnosed Cases of ITP in the United Kingdom (2016-2027)
Table 73: Diagnosed cases of CIT in the United Kingdom (2016-2027)
Table 74: Diagnosed cases of HIT in the United Kingdom (2016-2027)
Table 75: Diagnosed cases of Thrombocytopenia associated with CLD in the United Kingdom (2016-2027)
Table 76: Prevalent Cases of Thrombocytopenia in Japan (2016-2027)
Table 77: Prevalent Cases of TTP by Type in Japan (2016-2027)
Table 78: Prevalent Cases of TTP by Age in Japan (2016-2027)
Table 79: Prevalent Cases of ITP in Japan (2016-2027)
Table 80: Prevalent cases of CIT in Japan (2016-2027)
Table 81: Prevalent cases of HIT in Japan (2016-2027)
Table 82: Prevalent cases of Thrombocytopenia associated with CLD in Japan (2016-2027)
Table 83: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Japan (2016-2027)
Table 84: Diagnosed Cases of ITP in Japan (2016-2027)
Table 85: Diagnosed cases of CIT in Japan (2016-2027)
Table 86: Diagnosed cases of HIT in Japan (2016-2027)
Table 87: Diagnosed cases of Thrombocytopenia associated with CLD in Japan (2016-2027)
Table 91: Avatrombopag, Clinical Trial Description, 2018
Table 92:Fostamatinib, Clinical Trial Description, 2018
Table 93: Caplacizumab, Clinical Trial Description, 2018
Table 94: BT-595, Clinical Trial Description, 2018
Table 95: SHP 655, Clinical Trial Description, 2018
Table 96: PRN1008, Clinical Trial Description, 2018
Table 97: PRTX-100, Clinical Trial Description, 2018
Table 98: Rozanolixizumab, Clinical Trial Description, 2018
Table 99: Efgartigimod, Clinical Trial Description, 2018
Table 100: Veltuzumab, Clinical Trial Description, 2018
Table 101: 7MM Major Market Size of Thrombocytopenia in USD Million (2016-2027)
Table 102: Type Specific Market Size of Thrombocytopenia in 7MM (2016-2027)
Table 103: Market Size of Thrombocytopenia in the US, USD Million (2016-2027)
Table 104: Type Specific Market Size of Thrombocytopenia in the US (2016-2027)
Table 105: Market Size of TTP in the US in USD Million (2016-2027)
Table 106: Therapy Based Market Size of TTP in the US (2016-2027)
Table 107: Therapy Based Market Size of ITP in the US (2016-2027)
Table 108: Market Size of Thrombocytopenia in Germany, USD Million (2016-2027)
Table 109: Type Specific Market Size of Thrombocytopenia in Germany (2016-2027)
Table 110: Market Size of TTP in Germany in USD Million (2016-2027)
Table 111: Therapy Based Market Size of TTP in Germany (2016-2027)
Table 112: Therapy Based Market Size of ITP in Germany (2016-2027)
Table 113: Market Size of Thrombocytopenia in France, USD Million (2016-2027)
Table 114: Type Specific Market Size of Thrombocytopenia in France (2016-2027)
Table 115: Market Size of TTP in France in USD Million (2016-2027)
Table 116: Therapy Based Market Size of TTP in France (2016-2027)
Table 117: Therapy Based Market Size of ITP in France (2016-2027)
Table 118: Market Size of Thrombocytopenia in Italy, USD Million (2016-2027)
Table 119: Type Specific Market Size of Thrombocytopenia in Italy (2016-2027)
Table 120: Market Size of TTP in Italy in USD Million (2016-2027)
Table 121: Therapy Based Market Size of TTP in Italy (2016-2027)
Table 122: Therapy Based Market Size of ITP in Italy (2016-2027)
Table 123: Market Size of Thrombocytopenia in Spain, USD Million (2016-2027)
Table 124: Type Specific Market Size of Thrombocytopenia in Spain (2016-2027)
Table 125: Market Size of TTP in Spain in USD Million (2016-2027)
Table 126: Therapy Based Market Size of TTP in Spain (2016-2027)
Table 127: Therapy Based Market Size of ITP in Spain (2016-2027)
Table 128: Market Size of Thrombocytopenia in the UK, USD Million (2016-2027)
Table 129: Type Specific Market Size of Thrombocytopenia in the UK (2016-2027)
Table 130: Market Size of TTP in the UK in USD Million (2016-2027)
Table 131: Therapy Based Market Size of TTP in the UK (2016-2027)
Table 132: Therapy Based Market Size of ITP in the UK (2016-2027)
Table 133: Market Size of Thrombocytopenia in Japan, USD Million (2016-2027)
Table 134: Type Specific Market Size of Thrombocytopenia in Japan (2016-2027)
Table 135: Therapy Based Market Size of ITP in Japan (2016-2027)
Figure 1: Cellular pathogenic mechanisms in immune thrombocytopenia (ITP)
Figure 2: Schematic representation of pathophysiology of cITP
Figure 3: Algorithm for management of thrombocytopenia
Figure 4: Diagnosis and treatment algorithm for Thrombotic microangiopathy
Figure 5: Diagnosis and treatment algorithm for Heparin-induced Thrombocytopenia
Figure 6: Direct Thrombin Inhibitor (DTI) Dosing and Monitoring
Figure 7: Prevalent Population of Thrombocytopenia in the 7MM (2016-2027)
Figure 8: Prevalent cases of Thrombocytopenia in the United States (2016-2027)
Figure 9: Prevalent cases of TTP by Type in the United States (2016-2027)
Figure 10: Prevalent cases of TTP by Age in the United States (2016-2027)
Figure 11: Prevalent Cases of ITP in the United States (2016-2027)
Figure 12: Prevalent cases of CIT in the United States (2016-2027)
Figure 13: Prevalent cases of HIT in the United States (2016-2027)
Figure 14: Prevalent cases of Thrombocytopenia associated with CLD in the United States (2016-2027)
Figure 15: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United States (2016-2027)
Figure 16: Diagnosed Cases of ITP in the United States (2016-2027)
Figure 17: Diagnosed cases of CIT in the United States (2016-2027)
Figure 18: Diagnosed cases of HIT in the United States (2016-2027)
Figure 19: Diagnosed cases of Thrombocytopenia associated with CLD in the United States (2016-2027)
Figure 20: Prevalent cases of Thrombocytopenia in Germany (2016-2027)
Figure 21: Prevalent cases of TTP by Type in Germany (2016-2027)
Figure 22: Prevalent cases of TTP by Age in Germany (2016-2027)
Figure 23: Prevalent Cases of ITP in Germany (2016-2027)
Figure 24: Prevalent cases of CIT in Germany (2016-2027)
Figure 25: Prevalent cases of HIT in Germany (2016-2027)
Figure 26: Prevalent cases of Thrombocytopenia associated with CLD in Germany (2016-2027)
Figure 27: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Germany (2016-2027)
Figure 28: Diagnosed Cases of ITP in Germany (2016-2027)
Figure 29: Diagnosed cases of CIT in Germany (2016-2027)
Figure 30: Diagnosed cases of HIT in Germany (2016-2027)
Figure 31: Diagnosed cases of Thrombocytopenia associated with CLD in Germany (2016-2027)
Figure 32: Prevalent cases of Thrombocytopenia in France (2016-2027)
Figure 33: Prevalent cases of TTP by Type in France (2016-2027)
Figure 34: Prevalent cases of TTP by Age in France (2016-2027)
Figure 35: Prevalent Cases of ITP in France (2016-2027)
Figure 36: Prevalent cases of CIT in France (2016-2027)
Figure 37: Prevalent cases of HIT in France (2016-2027)
Figure 38: Prevalent cases of Thrombocytopenia associated with CLD in France (2016-2027)
Figure 39: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in France (2016-2027)
Figure 40: Diagnosed Cases of ITP in France (2016-2027)
Figure 41: Diagnosed cases of CIT in France (2016-2027)
Figure 42: Diagnosed cases of HIT in France (2016-2027)
Figure 43: Diagnosed cases of Thrombocytopenia associated with CLD in France (2016-2027)
Figure 44: Prevalent cases of Thrombocytopenia in Italy (2016-2027)
Figure 45: Prevalent cases of TTP by Type in Italy (2016-2027)
Figure 46: Prevalent cases of TTP by Age in Italy (2016-2027)
Figure 47: Prevalent Cases of ITP in Italy (2016-2027)
Figure 48: Prevalent cases of CIT in Italy (2016-2027)
Figure 49: Prevalent cases of HIT in Italy (2016-2027)
Figure 50: Prevalent cases of Thrombocytopenia associated with CLD in Italy (2016-2027)
Figure 51: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Italy (2016-2027)
Figure 52: Diagnosed Cases of ITP in Italy (2016-2027)
Figure 53: Diagnosed cases of CIT in Italy (2016-2027)
Figure 54: Diagnosed cases of HIT in Italy (2016-2027)
Figure 55: Diagnosed cases of Thrombocytopenia associated with CLD in Italy (2016-2027)
Figure 56: Prevalent cases of Thrombocytopenia in Spain (2016-2027)
Figure 57: Prevalent cases of TTP by Type in Spain (2016-2027)
Figure 58: Prevalent cases of TTP by Age in Spain (2016-2027)
Figure 59: Prevalent Cases of ITP in Spain (2016-2027)
Figure 60: Prevalent cases of CIT in Spain (2016-2027)
Figure 61: Prevalent cases of HIT in Spain (2016-2027)
Figure 62: Prevalent cases of Thrombocytopenia associated with CLD in Spain (2016-2027)
Figure 63: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Spain (2016-2027)
Figure 64: Diagnosed Cases of ITP in Spain (2016-2027)
Figure 65: Diagnosed cases of CIT in Spain (2016-2027)
Figure 66: Diagnosed cases of HIT in Spain (2016-2027)
Figure 67: Diagnosed cases of Thrombocytopenia associated with CLD in Spain (2016-2027)
Figure 68: Prevalent cases of Thrombocytopenia in the United Kingdom (2016-2027)
Figure 69: Prevalent cases of TTP by Type in the United Kingdom (2016-2027)
Figure 70: Prevalent cases of TTP by Age in the United Kingdom (2016-2027)
Figure 71: Prevalent Cases of ITP in the United Kingdom (2016-2027)
Figure 72: Prevalent cases of CIT in the United Kingdom (2016-2027)
Figure 73: Prevalent cases of HIT in the United Kingdom (2016-2027)
Figure 74: Prevalent cases of Thrombocytopenia associated with CLD in the United Kingdom (2016-2027)
Figure 75: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United Kingdom (2016-2027)
Figure 76: Diagnosed Cases of ITP in the United Kingdom (2016-2027)
Figure 77: Diagnosed cases of CIT in the United Kingdom (2016-2027)
Figure 78: Diagnosed cases of HIT in the United Kingdom (2016-2027)
Figure 79: Diagnosed cases of Thrombocytopenia associated with CLD in the United Kingdom (2016-2027)
Figure 80: Prevalent cases of Thrombocytopenia in Japan (2016-2027)
Figure 81: Prevalent cases of TTP by Type in Japan (2016-2027)
Figure 82: Prevalent cases of TTP by Age in Japan (2016-2027)
Figure 83: Prevalent Cases of ITP in Japan (2016-2027)
Figure 84: Prevalent cases of CIT in Japan (2016-2027)
Figure 85: Prevalent cases of HIT in Japan (2016-2027)
Figure 86: Prevalent cases of Thrombocytopenia associated with CLD in Japan (2016-2027)
Figure 87: Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Japan (2016-2027)
Figure 88: Diagnosed Cases of ITP in Japan (2016-2027)
Figure 89: Diagnosed cases of CIT in Japan (2016-2027)
Figure 90: Diagnosed cases of HIT in Japan (2016-2027)
Figure 91: Diagnosed cases of Thrombocytopenia associated with CLD in Japan (2016-2027)
Figure 95: Unmet Needs for Thrombocytopenia
Figure 97: 7 Major Market Size of Thrombocytopenia in USD Million (2016-2027)
Figure 98: Type Specific Market Size of Thrombocytopenia in 7MM (2016-2027)
Figure 99: Market Size of Thrombocytopenia in the US, USD Million (2016-2027)
Figure 100: Type Specific Market Size of Thrombocytopenia in the US (2016-2027)
Figure 101: Market Size of TTP in the US in USD Million (2016-2027)
Figure 102: Therapy Based Market Size of TTP in the US (2016-2027)
Figure 103: Therapy Based Market Size of ITP in the US (2016-2027)
Figure 104: Market Size of Thrombocytopenia in Germany, USD Million (2016-2027)
Figure 105: Type Specific Market Size of Thrombocytopenia in Germany (2016-2027)
Figure 106: Market Size of TTP in Germany USD Million (2016-2027)
Figure 107: Therapy Based Market Size of TTP in Germany (2016-2027)
Figure 108: Therapy Based Market Size of ITP in Germany (2016-2027)
Figure 109: Market Size of Thrombocytopenia in France, USD Million (2016-2027)
Figure 110: Type Specific Market Size of Thrombocytopenia in France (2016-2027)
Figure 111: Market Size of TTP in France in USD Million (2016-2027)
Figure 112: Therapy Based Market Size of TTP in France (2016-2027)
Figure 113: Therapy Based Market Size of ITP in France (2016-2027)
Figure 114: Market Size of Thrombocytopenia in Italy, USD Million (2016-2027)
Figure 115: Type Specific Market Size of Thrombocytopenia in Italy (2016-2027)
Figure 116: Market Size of TTP in Italy in USD Million (2016-2027)
Figure 117: Therapy Based Market Size of TTP in Italy (2016-2027)
Figure 118: Therapy Based Market Size of ITP in Italy (2016-2027)
Figure 119: Market Size of Thrombocytopenia in Spain, USD Million (2016-2027)
Figure 120: Type Specific Market Size of Thrombocytopenia in Spain (2016-2027)
Figure 121: Market Size of TTP in Spain in USD Million (2016-2027)
Figure 122: Therapy Based Market Size of TTP in Spain (2016-2027)
Figure 123: Therapy Based Market Size of ITP in Spain (2016-2027)
Figure 124: Market Size of Thrombocytopenia in the UK, USD Million (2016-2027)
Figure 125: Type Specific Market Size of Thrombocytopenia in the UK (2016-2027)
Figure 126: Market Size of TTP in the UK in USD Million (2016-2027)
Figure 127: Therapy Based Market Size of TTP in the UK (2016-2027)
Figure 128: Therapy Based Market Size of ITP in the UK (2016-2027)
Figure 129: Market Size of Thrombocytopenia in Japan, USD Million (2016-2027)
Figure 130: Type Specific Market Size of Thrombocytopenia in Japan (2016-2027)
Figure 131: Therapy Based Market Size of ITP in Japan (2016-2027)
Figure 132: Market Drivers for Thrombocytopenia
Figure 133: Market Barriers for Thrombocytopenia
